NCT03185871 2019-11-15
Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses
University of Wisconsin, Madison
Phase 2 Withdrawn
Clinical Trials
11 trialsNCT02839694 2018-07-05
Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT02615574 2017-09-26
A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer
University of Pittsburgh
Phase 2 Withdrawn
NCT00093678 2015-10-08
Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer
Eastern Cooperative Oncology Group
Phase NA Withdrawn
NCT00108186 2014-10-29
Celecoxib Treatment for Lung Cancer
VA Office of Research and Development
Phase 1 Withdrawn
NCT00072540 2013-11-08
S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT00084370 2013-08-22
Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy
University of Alabama at Birmingham
Phase NA Withdrawn
NCT00027976 2013-08-05
Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses
University of Alabama at Birmingham
Phase 2/3 Withdrawn
NCT00084578 2013-07-15
Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder
Fox Chase Cancer Center
Phase NA Withdrawn
NCT00025051 2013-03-22
Celecoxib in Preventing Skin Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00293436 2012-09-17
Celecoxib and Erlotinib in Treating Patients With Liver Cancer
University of California, San Francisco
Phase 1/2 Withdrawn